Metlife (MET) Stock Forecast & Price Target

Compare

2,831 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

MET Analyst Ratings

Strong Buy

10 Buy

2 Hold

0 Sell

Based on 12 analysts giving stock ratings to

Metlife

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

MET Stock 12 Month Forecast

Average Price Target

$96.09

▲(23.67%Upside)

Based on 12 Wall Street analysts offering 12 month price targets for Metlife in the last 3 months. The average price target is $96.09 with a high forecast of $110.00 and a low forecast of $90.00. The average price target represents a 23.67% change from the last price of $77.70.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"66":"$66","111":"$111","77.25":"$77.3","88.5":"$88.5","99.75":"$99.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":110,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$110.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":96.09,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$96.09</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":90,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$90.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[66,77.25,88.5,99.75,111],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"Apr<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,81.09,83.31384615384616,85.53769230769231,87.76153846153846,89.98538461538462,92.20923076923077,94.43307692307692,96.65692307692308,98.88076923076923,101.10461538461539,103.32846153846154,105.55230769230769,107.77615384615385,{"y":110,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,81.09,82.24384615384616,83.39769230769231,84.55153846153847,85.70538461538462,86.85923076923078,88.01307692307692,89.16692307692308,90.32076923076923,91.47461538461539,92.62846153846154,93.7823076923077,94.93615384615384,{"y":96.09,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,81.09,81.77538461538462,82.46076923076923,83.14615384615385,83.83153846153846,84.51692307692308,85.2023076923077,85.8876923076923,86.57307692307693,87.25846153846155,87.94384615384615,88.62923076923077,89.31461538461538,{"y":90,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":67.9,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":73.63,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":75.89,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":80.1,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":76.82,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":85.69,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":80.76,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":85.33,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":85.55,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":80.56,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":75.21,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":78.68,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":81.09,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$110.00

Average Price Target$96.09

Lowest Price Target$90.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

TipRanks AITipRanks

Not Ranked

TipRanks

$89

Buy

14.54%

Upside

Reiterated

07/10/25

MetLife's stock benefits from strong financial performance and positive earnings call insights, particularly significant earnings growth and strategic risk management. While technical indicators show mixed signals, the valuation remains attractive, supporting the overall positive outlook.

Elyse GreenspanWells Fargo

Wells Fargo

$94→$97

Buy

24.84%

Upside

Reiterated

07/10/25

MetLife price target raised to $97 from $94 at Wells FargoMetLife price target raised to $97 from $94 at Wells Fargo

Ryan KruegerKBW

KBW

$95→$94

Buy

20.98%

Upside

Reiterated

07/09/25

KBW Sticks to Their Buy Rating for Metlife (MET)

Jimmy BhullarJ.P. Morgan

J.P. Morgan

$86→$95

Buy

22.27%

Upside

Reiterated

07/08/25

J.P. Morgan Reaffirms Their Buy Rating on Metlife (MET)

Alex ScottBarclays

Barclays

$88→$94

Buy

20.98%

Upside

Reiterated

07/07/25

MetLife price target raised to $94 from $88 at BarclaysMetLife price target raised to $94 from $88 at Barclays

John BarnidgePiper Sandler

Piper Sandler

$94

Buy

20.98%

Upside

Reiterated

07/03/25

Metlife (MET) Gets a Buy from Piper Sandler

Wilma BurdisRaymond James

Raymond James

―

Hold

―

Reiterated

06/30/25

Thomas GallagherEvercore ISI

Evercore ISI

$110

Buy

41.57%

Upside

Reiterated

06/24/25

Evercore ISI Sticks to Their Buy Rating for Metlife (MET)

Suneet KamathJefferies

Jefferies

$100

Buy

28.70%

Upside

Assigned

06/03/25

Metlife (MET) Receives a Buy from Jefferies

Jack MattenBMO Capital

BMO Capital

$73→$90

Hold

15.83%

Upside

Reiterated

05/20/25

BMO Capital Remains a Hold on Metlife (MET)

Bob HuangMorgan Stanley

Morgan Stanley

$94→$99

Buy

27.41%

Upside

Reiterated

05/19/25

Metlife (MET) Gets a Buy from Morgan Stanley

Joshua ShankerBank of America Securities

Bank of America Securities

$108→$94

Buy

20.98%

Upside

Reiterated

05/01/25

MetLife's Strategic Moves and Strong Group Benefits Performance Justify Buy Rating

Andrew KligermanTD Cowen

TD Cowen

$90

Buy

15.83%

Upside

Reiterated

05/01/25

Analysts' Top Financial Picks: TeraWulf Inc (WULF), Metlife (MET)

Brian MeredithUBS

UBS

$98

Buy

26.13%

Upside

Reiterated

04/02/25

Metlife (MET) Receives a Rating Update from a Top Analyst

Kevin HealArgus Research

Argus Research

$93

Buy

19.69%

Upside

Reiterated

02/25/25

Argus Research Keeps Their Buy Rating on Metlife (MET)

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

TipRanks AITipRanks

Not Ranked

TipRanks

$89

Buy

14.54%

Upside

Reiterated

07/10/25

Elyse GreenspanWells Fargo

Wells Fargo

$94→$97

Buy

24.84%

Upside

Reiterated

07/10/25

MetLife price target raised to $97 from $94 at Wells FargoMetLife price target raised to $97 from $94 at Wells Fargo

Ryan KruegerKBW

KBW

$95→$94

Buy

20.98%

Upside

Reiterated

07/09/25

KBW Sticks to Their Buy Rating for Metlife (MET)

Jimmy BhullarJ.P. Morgan

J.P. Morgan

$86→$95

Buy

22.27%

Upside

Reiterated

07/08/25

J.P. Morgan Reaffirms Their Buy Rating on Metlife (MET)

Alex ScottBarclays

Barclays

$88→$94

Buy

20.98%

Upside

Reiterated

07/07/25

MetLife price target raised to $94 from $88 at BarclaysMetLife price target raised to $94 from $88 at Barclays

John BarnidgePiper Sandler

Piper Sandler

$94

Buy

20.98%

Upside

Reiterated

07/03/25

Metlife (MET) Gets a Buy from Piper Sandler

Wilma BurdisRaymond James

Raymond James

―

Hold

―

Reiterated

06/30/25

Thomas GallagherEvercore ISI

Evercore ISI

$110

Buy

41.57%

Upside

Reiterated

06/24/25

Evercore ISI Sticks to Their Buy Rating for Metlife (MET)

Suneet KamathJefferies

Jefferies

$100

Buy

28.70%

Upside

Assigned

06/03/25

Metlife (MET) Receives a Buy from Jefferies

Jack MattenBMO Capital

BMO Capital

$73→$90

Hold

15.83%

Upside

Reiterated

05/20/25

BMO Capital Remains a Hold on Metlife (MET)

Bob HuangMorgan Stanley

Morgan Stanley

$94→$99

Buy

27.41%

Upside

Reiterated

05/19/25

Metlife (MET) Gets a Buy from Morgan Stanley

Joshua ShankerBank of America Securities

Bank of America Securities

$108→$94

Buy

20.98%

Upside

Reiterated

05/01/25

MetLife's Strategic Moves and Strong Group Benefits Performance Justify Buy Rating

Andrew KligermanTD Cowen

TD Cowen

$90

Buy

15.83%

Upside

Reiterated

05/01/25

Analysts' Top Financial Picks: TeraWulf Inc (WULF), Metlife (MET)

Brian MeredithUBS

UBS

$98

Buy

26.13%

Upside

Reiterated

04/02/25

Metlife (MET) Receives a Rating Update from a Top Analyst

Kevin HealArgus Research

Argus Research

$93

Buy

19.69%

Upside

Reiterated

02/25/25

Argus Research Keeps Their Buy Rating on Metlife (MET)

Stocks with the Highest Top Analyst Consensus in the Financial Sector

xxx

Find stocks in the Financial sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Metlife

1 Month

xxx

Success Rate

23/34 ratings generated profit

Average Return

+2.19%

assigned a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 67.65% of your transactions generating a profit, with an average return of +2.19% per trade.

3 Months

xxx

Success Rate

19/30 ratings generated profit

Average Return

+6.40%

reiterated a xxx

rating 6 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 63.33% of your transactions generating a profit, with an average return of +6.40% per trade.

1 Year

Ryan KruegerKBW

Success Rate

25/30 ratings generated profit

Average Return

+16.57%

reiterated a buy rating 6 days ago

Copying Ryan Krueger's trades and holding each position for 1 Year would result in 83.33% of your transactions generating a profit, with an average return of +16.57% per trade.

2 Years

xxx

Success Rate

25/31 ratings generated profit

Average Return

+15.75%

reiterated a xxx

rating 5 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 80.65% of your transactions generating a profit, with an average return of +15.75% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

MET Analyst Recommendation Trends

Rating

Mar 25

Apr 25

May 25

Jun 25

Jul 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, MET has received 19 Buy Ratings, 3 Hold Ratings, and 0 Sell Ratings. MET average Analyst price target in the past 3 months is 96.09.

Each month's total comprises the sum of three months' worth of ratings.

MET Financial Forecast

MET Earnings Forecast

Next quarter’s earnings estimate for MET is $2.16 with a range of $2.02 to $2.27. The previous quarter’s EPS was $1.96. MET beat its EPS estimate 25.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 64.71% of the time in the same period. In the last calendar year MET has Outperformed its overall industry.

MET Sales Forecast

Next quarter’s sales forecast for MET is $18.53B with a range of $17.83B to $19.28B. The previous quarter’s sales results were $18.57B. MET beat its sales estimates 50.00% of the time in past 12 months, while its overall industry beat sales estimates 78.95% of the time in the same period. In the last calendar year MET has Outperformed its overall industry.

MET Stock Forecast FAQ

What is MET’s average 12-month price target, according to analysts?

Based on analyst ratings, Metlife’s 12-month average price target is 96.09.

What is MET’s upside potential, based on the analysts’ average price target?

Metlife has 23.67% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is MET a Buy, Sell or Hold?

Metlife has a consensus rating of Strong Buy which is based on 10 buy ratings, 2 hold ratings and 0 sell ratings.

What is Metlife’s price target?

The average price target for Metlife is 96.09. This is based on 12 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $110.00 ,the lowest forecast is $90.00. The average price target represents 23.67% Increase from the current price of $77.7.

What do analysts say about Metlife?

Metlife’s analyst rating consensus is a Strong Buy. This is based on the ratings of 12 Wall Streets Analysts.

How can I buy shares of MET?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Metlife (MET) Stock Forecast & Price Target

MET Analyst Ratings

MET Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Metlife

MET Analyst Recommendation Trends

MET Financial Forecast

MET Earnings Forecast

MET Sales Forecast

MET Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts